CLSD - Clearside Biomedical, Inc.
Clearside Biomedical, Inc.
900 North Point Parkway
Suite 200
Alpharetta, GA 30005
United States
(678) 270-3631
https://clearsidebio.com
Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 36
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. George M. Lasezkay J.D., Pharm.D., Pharma.D. | Pres, CEO & Director | 816.4k | N/A | 1952 |
| Mr. Charles A. Deignan | Chief Financial Officer | 536.95k | N/A | 1964 |
| Dr. Thomas A. Ciulla M.B.A., M.D. | Chief Medical Advisor-Retina | 597.21k | N/A | 1965 |
| Ms. Jenny R. Kobin | Head of Investor Relations | N/A | N/A | 1967 |
| Mr. Rick McElheny | VP of Corp. Devel. | N/A | N/A | N/A |
| Mr. Rafael V. Andino | Sr. VP of Engineering & Manufacturing | N/A | N/A | 1965 |
| Ms. Susan L. Coultas Ph.D. | Chief Clinical Officer | N/A | N/A | N/A |
| Mr. Leslie B. Zacks | Sec. | N/A | N/A | 1969 |
Description
Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase 1/2a clinical trial; and CLS-301, an integrin inhibitor suspension for the treatment of diabetic macular edema and macular degeneration. Clearside Biomedical, Inc. has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., and Aura Biosciences. The company was incorporated in 2011 and is headquartered in Alpharetta, Georgia.
Corporate Governance
Clearside Biomedical, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
